3 results match your criteria: "The First Affiliation Hospital of China Medical University[Affiliation]"
Development and validation of a prognostic model based on m6A-related lncRNAs to predict prognosis for papillary renal cell cancer patients.
Sci Rep
December 2024
Department of Urology Surgery, The First Affiliation Hospital of China Medical University, Shenyang, 110000, Liaoning, China.
To evaluate the predictive utility of N6-methyladenosine (m6A)-associated long non-coding RNAs (lncRNAs) for the prognosis and immunotherapy response in papillary renal cell carcinoma (pRCC). Transcriptomic data of pRCC samples were extracted from the TCGA database. The m6A-related lncRNAs were identified by Pearson correlation analysis.
View Article and Find Full Text PDFGenetic correlation between chronic sinusitis and autoimmune diseases.
Front Allergy
September 2024
Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
Article Synopsis
- The study investigates the genetic links between chronic rhinosinusitis (CRS) and various autoimmune diseases to clarify their association, which is not well understood.
- Researchers utilized methods like Mendelian randomization and transcriptome-wide association to analyze data from several genetic databases.
- Results indicate significant associations, showing that CRS is genetically correlated with autoimmune conditions like allergic rhinitis, asthma, rheumatoid arthritis, hypothyroidism, and type 1 diabetes.
The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
Front Endocrinol (Lausanne)
February 2023
Department of Urology Surgery, The First Affiliation Hospital of China Medical University, Shenyang, China.
Background: Second-generation androgen receptor inhibitors (ARIs) have been developed and approved for treating castration-resistant prostate cancer (CRPC). There is a lack of direct comparison of the therapeutic effects and adverse events between the conventional ARI (bicalutamide) and three second-generation ARIs (enzalutamide, apalutamide and darolutamide).
Methods: Our network meta-analysis evaluated therapeutic effects and adverse events of the conventional ARI (bicalutamide) and the second-generation ARIs in treating CRPC.